|End-of-day quote - 11/26|
Starpharma Releases New Data About SPL701306/17/2021 | 07:23pm
Starpharma released new data demonstrating that SPL7013, the active in VIRALEZETM antiviral nasal spray, achieved more than 99.9% reduction of virus against the Alpha (UK), Beta (South Africa) and Gamma (Japan/Brazil) SARS-CoV-2 coronavirus `Variants of Concern' in laboratory-based virucidal assays. The testing of SPL7013 was conducted in the laboratory of virologist Professor Philippe Gallay at The Scripps Research Institute in the US, where previous studies have demonstrated potent antiviral and virucidal activity of SPL7013 against multiple strains of SARS-CoV-2. 2 SPL7013 virucidal activity against the Alpha, Beta and Gamma variants in the current assays were broadly consistent with the virucidal activity demonstrated in the US strain of SARS-CoV- 2 (2019-nCoV/USA-WA1/2020) in the same assay. Within 30 seconds to 1 minute of exposure, SPL7013 achieved >99% reduction in infectious virus against Beta and Gamma variants, and >99.9% within 5 minutes, and for Alpha, >99.9% reduction in infectious virus within 30 seconds to 1 minute of exposure vs virus control. These findings indicate comparable potency for SPL7013 against all three variants of concern Alpha, Beta and Gamma compared with original strains of the virus. The Delta (India/B.1.617.2) and Kappa (India/B.1.617.1) variants are planned to be tested when virus availability permits.
© S&P Capital IQ 2021
All news about STARPHARMA HOLDINGS LIMITED